3 minute read
Community Fundraising
City2Surf
The City2Surf returned in style, with 60,000 participants running, walking, and dancing their way through the city to the sun-drenched Bondi Beach, after two years of virtual races on Sunday 14 August. Steven Guy was one of those walkers and fundraisers, whose mission was to walk for cancer.
“My name is Steve, and I was first diagnosed with kidney cancer in April 2019, it rapidly metastasized. Now, after 3 years where I have had 3 major surgeries, numerous procedures and ongoing treatments and tests, I have decided to try to give something back by raising money from walking the 14km City2Surf in August 2022 in under 3 hours”.
Steven raised an incredible $1,441.50 for ANZUP and below the belt cancer research and walked 14 kilometres in 2 hours and 21 minutes. An incredible effort and commitment to raising funds and awareness to improve outcomes for kidney cancer. Interested in joining a public event and raising funds for ANZUP? Go to belowthebelt.org.au/event-listings for current event listings.
STEVEN GUY BEFORE, DURING AND AT THE FINISH LINE, OF THE CITY TO SURF.
Breakfast Point Men’s Shed
John and the Breakfast Point Men’s Shed team have been great supporters of ANZUP since 2018 at our Pedalthon events, and local community events to raise funds and awareness for below the belt cancer. In August the Men’s Shed with the support of IGA Breakfast Point put on a community sausage sizzle. Despite a windy morning, the sausage sizzle welcomed over 100 people and raised over $1,300 funds to go towards the Sydney Pedalthon and below the belt clinical trials research. Many thanks to the Breakfast Point Men’s Shed for their outstanding efforts to raise awareness and funds for the Sydney Pedalthon. They raised over $20,000!!!!
THE BREAKFAST POINT MEN’S SHED SAUSAGE SIZZLE
Dry-Gust
In August, ANZUP encouraged supporters to go dry and make a difference to the lives of people affected by below the belt cancers. Charlie Harris put his hand up for the challenge and raised $234. Charlie went booze free throughout the month of August and feeling the benefits!
Host your own fundraiser and help us fight cancer, below the belt
Rum, ride, go without your daily coffee, host a garage sale, or bake your heart out. The sky is the limit when it comes to hosting your own fundraiser. No matter where you are across Australia or New Zealand, or around the world, you can use your skills and interests to get involved and help fight below the belt cancers. So far, through our Below the Belts events we have raised over $1.96 million and funded 36 new cancer research projects. Get involved today and help support more projects to improve the lives and outcomes for those living with below the belt cancers.
https://www.belowthebelt.org.au/funraiseyourway
We are pleased to announce that in the recent funding round for Perpetual’s 2022 IMPACT Philanthropy Program, ANZUP was awarded two grants.
1. TheraP Translational Research.
ANZUP’s TheraP trial showed that Lu-PSMA is more effective than chemotherapy in advanced prostate cancer. Although this is very promising and exciting, we know that not all people benefit from Lu-PSMA and after a period, the treatment stops working in all people. We have developed technology to pick up tiny amounts of DNA (the genetic blueprint) released by cancer cells into the bloodstream. This is also referred to as circulating tumour DNA (ctDNA). By testing ctDNA in the laboratory from blood samples collected on the TheraP trial, we will try to understand which people get excellent responses to treatment, which people never respond to treatment, and also what causes Lu-PSMA to stop working. Many thanks to the Centenary Foundation – Betty Lowe Memorial, Centenary Foundation – Robert William Alfred Blackburn, Hillcrest Foundation and James & Barbara Quinn & Family Foundation for their funding towards this important work.
2. UNISoN Kidney Cancer Genetic
Analysis.
By reviewing kidney cancer samples and blood tests donated by the people on the UNISoN kidney cancer clinical trial, we hope to learn if we can predict which people who have rare variant kidney cancer are most likely to benefit from treatment, who needs one drug and who needs two. We have planned a suite of different scientific experiments to test these samples and compare them to the outcomes of people on the UNISoN trial. Many thanks to the Hillcrest Foundation for their generous funding.
